TAp63α Cancer Research Results

TAp63α, TAp63α: Click to Expand ⟱
Source:
Type:
TAp63α is a protein isoform of the p63 gene, which is a member of the p53 family of transcription factors. p63 is involved in various cellular processes, including development, cell cycle regulation, and apoptosis.

TAp63α has been implicated in cancer development and progression. It is often overexpressed in various types of cancer, including breast, lung, and head and neck cancers. The overexpression of TAp63α has been associated with poor prognosis and aggressive tumor behavior.

In multiple cancers, lower expression of the tumor‐suppressive TAp63α isoform tends to correlate with a more aggressive clinical course and poorer overall survival.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
168- CUR,    Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism
- in-vitro, Pca, PC3
Akt↓, mTOR↓, AMPK↑, TAp63α↑, TumCP↓,
87- QC,    Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ROS⇅, BAX↑, PUMA⇅, β-catenin/ZEB1↓, Shc↓, TAp63α↑, MAPK↑, p‑p42↑, p‑p44↑, BIM↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS⇅, 1,  

Mitochondria & Bioenergetics ⓘ

p‑p42↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,  

Cell Death ⓘ

Akt↓, 1,   BAX↑, 1,   BIM↑, 1,   MAPK↑, 1,   PUMA⇅, 1,  

Transcription & Epigenetics ⓘ

Shc↓, 1,  

Cell Cycle & Senescence ⓘ

TAp63α↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↓, 1,  

Migration ⓘ

p‑p44↑, 1,   TumCP↓, 1,   β-catenin/ZEB1↓, 1,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TAp63α, TAp63α
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:432  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page